Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
Heritable changes in gene expression that are not based upon alterations in the DNA sequence are defined as epigenetics. The most common mechanisms of epigenetic regulation are the methylation of CpG islands within the DNA and the modification of amino acids in the N-terminal histone tails. In the last years, it became evident that the onset of cancer and its progression may not occur only due to genetic mutations but also because of changes in the patterns of epigenetic modifications. In contrast to genetic mutations, which are almost impossible to reverse, epigenetic changes are potentially reversible. This implies that they are amenable to pharmacological interventions. Therefore, a lot of work in recent years has focussed on the development of small molecule enzyme inhibitors like DNA-methyltransferase inhibitors or inhibitors of histone-modifying enzymes. These may reverse misregulated epigenetic states and be implemented in the treatment of cancer or other diseases, e.g., neurological disorders. Today, several epigenetic drugs are already approved by the FDA and the EMEA for cancer treatment and around ten histone deacetylase (HDAC) inhibitors are in clinical development. This review will give an update on recent clinical trials of the HDAC inhibitors used systemically that were reported in 2009 and 2010 and will present an overview of different biomarkers to monitor the biological effects.
Julia M
JM
Wagner
Björn
B
Hackanson
Michael
M
Lübbert
Manfred
M
Jung
Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S17-9
11587360
Oncogene. 2004 Mar 4;23(9):1724-36
14676837
Cancer Lett. 2009 Aug 8;280(2):233-41
19344997
Biochem Pharmacol. 1997 Jun 1;53(11):1719-24
9264325
EMBO J. 2001 Dec 17;20(24):6969-78
11742974
Br J Cancer. 2009 Jan 13;100(1):28-36
19127265
Cancer. 2009 Dec 1;115(23):5541-9
19711464
Nat Rev Cancer. 2006 Jan;6(1):38-51
16397526
Clin Cancer Res. 2009 May 1;15(9):3189-95
19383814
Mol Cancer Ther. 2010 Mar;9(3):642-52
20197387
J Immunol. 2000 Dec 15;165(12):7017-24
11120829
Circ Res. 2002 Nov 1;91(9):837-44
12411399
Cell. 2009 Sep 4;138(5):1019-31
19698979
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7
9501205
Cancer Res. 2003 Jun 15;63(12):3069-72
12810630
BMC Cancer. 2007 Nov 30;7:220
18047684
Cancer Res. 2001 Oct 1;61(19):7025-9
11585728
Cancer Chemother Pharmacol. 2010 Apr;65(5):979-88
20062993
Drugs. 2009 Oct 1;69(14):1911-34
19747008
Nucleic Acids Res. 1999 May 1;27(9):2057-8
10198441
Blood. 2008 Feb 1;111(3):1060-6
17962510
Oncotarget. 2010 May;1(1):34-42
21293051
Oncogene. 2004 Aug 19;23(37):6304-15
15318170
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
16955068
J Med Chem. 1999 Jul 29;42(15):3001-3
10425110
Trends Genet. 2003 May;19(5):286-93
12711221
Annu Rev Biochem. 2006;75:435-65
16756498
Cancer Lett. 2009 Aug 8;280(2):168-76
19103471
Leuk Lymphoma. 2003;44 Suppl 3:S5-12
15202519
Lancet Oncol. 2010 May;11(5):459-64
20378407
Cancer Lett. 2009 Aug 8;280(2):160-7
19342155
Nat Rev Drug Discov. 2008 Oct;7(10):854-68
18827828
Clin Cancer Res. 2009 Aug 15;15(16):5250-7
19671864
Breast Cancer Res Treat. 2007 Nov;105(3):297-309
17186358
Gene Expr. 1996;5(4-5):245-53
8723390
Mutat Res. 2008 Mar-Apr;658(3):191-214
18403253
Methods Enzymol. 2004;377:180-96
14979025
Cancer Biol Ther. 2005 Sep;4(9):956-60
16082189
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6532-7
20308564
Br J Cancer. 1999 Jun;80(8):1252-8
10376979
Cancer Biol Ther. 2007 Jan;6(1):64-9
17172825
Blood. 2003 Oct 1;102(7):2615-22
12816865
Eur J Cancer. 2010 Jun;46(9):1573-9
20304628
J Clin Oncol. 2010 Jan 1;28(1):56-62
19933908
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3921-6
15001702
Int J Biochem Cell Biol. 2007;39(7-8):1388-405
17383217
Mol Cancer Ther. 2003 Aug;2(8):721-8
12939461
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
10954755
Haematologica. 2009 Oct;94(10):1375-82
19794082
Mol Pharmacol. 2005 Dec;68(6):1852-62
16186250
Cancer Sci. 2010 Jan;101(1):196-200
19817748
Ann Hematol. 2010 Feb;89(2):185-90
19633847
Cancer Chemother Pharmacol. 2010 May;66(1):181-9
20217089
Clin Cancer Res. 2009 Apr 1;15(7):2479-87
19318485
Oncogene. 2006 Mar 16;25(12):1799-806
16158045
Clin Cancer Res. 2009 Apr 1;15(7):2488-96
19318486
Cell. 2007 Feb 23;128(4):683-92
17320506
J Thorac Oncol. 2009 Jan;4(1):97-101
19096314
Cancer Sci. 2009 Sep;100(9):1728-34
19575752
Blood. 2009 Sep 24;114(13):2764-73
19546476
Clin Cancer Res. 2009 Oct 1;15(19):6241-9
19789320
Blood. 2010 Oct 14;116(15):2732-41
20566897
Cancer Cell. 2010 May 18;17(5):427-42
20478526
Mol Pharmacol. 2004 Mar;65(3):520-7
14978230
Clin Cancer Res. 2008 Jun 1;14(11):3441-9
18519775
Anal Biochem. 2003 Aug 1;319(1):42-8
12842105
Curr Cancer Drug Targets. 2009 Dec;9(8):963-81
20025605
J Clin Oncol. 2009 Apr 20;27(12):2052-8
19307505
Biochem Biophys Res Commun. 2008 Apr 18;368(4):959-64
18275843
Neuropsychopharmacology. 2010 Mar;35(4):870-80
20010553
Oncogene. 2004 Sep 2;23(40):6693-701
15235588
J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5
9811311
Br J Cancer. 2007 Nov 19;97(10):1344-53
18000499
Nat Rev Genet. 2009 Jan;10(1):32-42
19065135
Nat Rev Drug Discov. 2006 Jan;5(1):37-50
16485345
BMC Med Genomics. 2009 Nov 30;2:67
19948057
Melanoma Res. 2008 Aug;18(4):274-8
18626312
J Biol Chem. 2006 Feb 3;281(5):2401-4
16272578
Blood. 2006 Feb 15;107(4):1546-54
16223781
Nat Chem Biol. 2010 Mar;6(3):238-243
20139990
Invest New Drugs. 2009 Oct;27(5):469-75
18941712
Cancer Res. 2002 Sep 1;62(17):4916-21
12208741
Anticancer Drugs. 2009 Sep;20(8):682-92
19606018
Mol Cancer Ther. 2008 Apr;7(4):759-68
18413790
Cancer Res. 2008 May 15;68(10):3785-94
18483262
Oncogene. 2005 Jul 21;24(31):4894-907
15870696
J Clin Oncol. 2009 Nov 10;27(32):5410-7
19826128
Cancer Lett. 2009 Aug 8;280(2):177-83
19362413
Mol Cancer Res. 2008 Jul;6(7):1250-8
18644987
Oncogene. 2002 Jan 17;21(3):427-36
11821955
Ann Oncol. 2010 Jan;21(1):109-13
19608618
Gene. 2005 Dec 19;363:15-23
16289629
Mol Cell Biol. 2002 Jul;22(13):4902-13
12052895
Leukemia. 2007 Sep;21(9):1892-900
17637810
Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):213-30
16866608
Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5
20392638
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
10200307
Science. 1975 Nov 28;190(4217):893-4
1059262
Br J Cancer. 2009 Oct 6;101(7):1044-50
19738609
Br J Haematol. 2009 Nov;147(4):507-14
19747365
EMBO Rep. 2001 Oct;2(10):933-8
11571271
Clin Cancer Res. 2009 Aug 1;15(15):5002-7
19638460
Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9
18829438
Cancer Cell. 2009 Jan 6;15(1):57-66
19111881
Blood. 2007 Apr 1;109(7):2781-90
17179232
Eur J Cancer. 2005 Nov;41(16):2381-402
16226460
J Clin Oncol. 2009 Mar 1;27(7):1075-81
19139427